Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On January 23, 2017, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2016 and the completion of the restatement of its financial statements. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit to Item 7.01 hereof:

Exhibit 99.1 — Press Release Dated January 23, 2017.


About Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Recent Trading Information

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) closed its last trading session up +0.73 at 25.60 with 423,252 shares trading hands.